Swiss pharmaceutical giant Novartis risks seeing some of its medicines banned in South Korea after company executives were charged with offering illegal discounts to doctors, the Financial Times reported Thursday.
According to the British business daily, South Korean prosecutors have asked the government to suspend the operations of Novartis Korea after six executives at the unit, including its president, were indicted for allegedly handing out $2.4-million (2.1-million euros) in illegal rebates from 2011 to 2016, in a move that could see the sale of implicated medicines banned for up to six months.
Novartis told AFP in an email that it would "take time to review the details of the indictment thoroughly and consider our next steps."